<DOC>
	<DOCNO>NCT01272583</DOCNO>
	<brief_summary>Hypoglycaemia well-known complication insulin treat diabetes . The counterregulatory response hypoglycaemia , glucagon important mediator , initially diminish within year onset Type 1 diabetes subsequently lose thus increase risk hypoglycaemia . Dipeptidyl Peptidase ( DPP ) -4 inhibitor augment glucagon response insulin-induced hypoglycaemia type 2 diabetes . The investigator hypothesize treatment DPP-4 inhibitor patient type 1 diabetes recover alpha cell response hypoglycaemia .</brief_summary>
	<brief_title>Dipeptidyl Peptidase-4 Inhibitors Alpha-cell Recovery</brief_title>
	<detailed_description>The 16 type 1 patient randomise one two treatment sequence : DPP-4 inhibitor follow placebo placebo follow DPP-4 inhibitor . Each treatment period last 6 week , patient receive treatment 12 week total . Induction hypoglycaemia take place 0 week , 6 week 12 week determine glucagon response .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Type 1 Diabetes Mellitus 520 year duration Cpeptide negative Willing able give write informed consent Impaired awareness hypoglycaemia BMI &gt; 27 kg/m2 Evidence severe diabetes complication ( autonomic neuropathy , macroalbuminuria , proliferative retinopathy ) Acute illness within 3 month study Significant renal impairment ( creatinine clearance &lt; 50ml/min ) Use betaadrenoreceptor blocker Cardiac history ( previous arrhythmia ) History epilepsy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>Glucagon</keyword>
</DOC>